715 related articles for article (PubMed ID: 18632907)
1. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study.
González GM; Elizondo M; Ayala J
J Clin Microbiol; 2008 Sep; 46(9):2902-5. PubMed ID: 18632907
[TBL] [Abstract][Full Text] [Related]
2. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
3. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
Karabıçak N; Alem N
Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology and Antifungal Susceptibility of
Badiee P; Boekhout T; Haddadi P; Mohammadi R; Ghadimi-Moghadam A; Soltani J; Zarei Mahmoudabadi A; Ayatollahi Mousavi SA; Najafzadeh MJ; Diba K; Salimi-Khorashad AR; Amin Shahidi M; Ghasemi F; Jafarian H
Microbiol Spectr; 2022 Dec; 10(6):e0245322. PubMed ID: 36445122
[TBL] [Abstract][Full Text] [Related]
5. Identification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey.
Dagi HT; Findik D; Senkeles C; Arslan U
Ann Clin Microbiol Antimicrob; 2016 May; 15(1):36. PubMed ID: 27245756
[TBL] [Abstract][Full Text] [Related]
6. Species distribution and antifungal susceptibility of Candida bloodstream isolates in a tertiary medical center in Israel.
Samra Z; Yardeni M; Peled N; Bishara J
Eur J Clin Microbiol Infect Dis; 2005 Sep; 24(9):592-5. PubMed ID: 16172856
[TBL] [Abstract][Full Text] [Related]
7. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
8. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
[TBL] [Abstract][Full Text] [Related]
9. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.
Panizo MM; Reviákina V; Dolande M; Selgrad S
Med Mycol; 2009 Mar; 47(2):137-43. PubMed ID: 18651308
[TBL] [Abstract][Full Text] [Related]
10. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program.
Pfaller MA; Diekema DJ; Jones RN; Sader HS; Fluit AC; Hollis RJ; Messer SA;
J Clin Microbiol; 2001 Sep; 39(9):3254-9. PubMed ID: 11526159
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish University Hospital.
Arikan S; Sancak B; Hascelik G
Med Mycol; 2005 Mar; 43(2):171-8. PubMed ID: 15832560
[TBL] [Abstract][Full Text] [Related]
12. In vitro evaluation of antibiotic lock technique for the treatment of Candida albicans, C. glabrata, and C. tropicalis biofilms.
Ko KS; Lee JY; Song JH; Peck KR
J Korean Med Sci; 2010 Dec; 25(12):1722-6. PubMed ID: 21165285
[TBL] [Abstract][Full Text] [Related]
13. Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011.
Guinea J; Zaragoza Ó; Escribano P; Martín-Mazuelos E; Pemán J; Sánchez-Reus F; Cuenca-Estrella M;
Antimicrob Agents Chemother; 2014; 58(3):1529-37. PubMed ID: 24366741
[TBL] [Abstract][Full Text] [Related]
14. Fluconazole exposure rather than clonal spreading is correlated with the emergence of Candida glabrata with cross-resistance to triazole antifungal agents.
Chen TC; Chen YH; Chen YC; Lu PL
Kaohsiung J Med Sci; 2012 Jun; 28(6):306-15. PubMed ID: 22632885
[TBL] [Abstract][Full Text] [Related]
15. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
[TBL] [Abstract][Full Text] [Related]
16. Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination.
Castanheira M; Deshpande LM; Messer SA; Rhomberg PR; Pfaller MA
Int J Antimicrob Agents; 2020 Jan; 55(1):105799. PubMed ID: 31520783
[TBL] [Abstract][Full Text] [Related]
17. Species distribution and antifungal drug susceptibilities of yeasts isolated from the blood samples of patients with candidemia.
Lindberg E; Hammarström H; Ataollahy N; Kondori N
Sci Rep; 2019 Mar; 9(1):3838. PubMed ID: 30846717
[TBL] [Abstract][Full Text] [Related]
18. In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates.
Swinne D; Watelle M; Nolard N
Rev Iberoam Micol; 2005 Mar; 22(1):24-8. PubMed ID: 15813679
[TBL] [Abstract][Full Text] [Related]
19. In vitro susceptibility of oral Candida to seven antifungal agents.
Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
[TBL] [Abstract][Full Text] [Related]
20. [Study on in vitro susceptibility of Candida spp. isolated from blood culture].
Grandesso S; Sapino B; Mazzuccato S; Solinas M; Bedin M; D'Angelo M; Gion M
Infez Med; 2012 Mar; 20(1):25-30. PubMed ID: 22475657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
